Open AccessCanine atopic dermatitis: Role of luteolin as new natural treatment
Author(s) -
Gugliandolo Enrico,
Palma Ernesto,
Cordaro Marika,
D’Amico Ramona,
Peritore Alessio Filippo,
Licata Patrizia,
Crupi Rosalia
Publication year - 2020
Publication title -
veterinary medicine and science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.485
H-Index - 11
ISSN - 2053-1095
DOI - 10.1002/vms3.325
Subject(s) - luteolin , atopic dermatitis , pharmacology , ec50 , medicine , toxicity , stimulation , in vitro , antioxidant , chemistry , immunology , biochemistry , flavonoid
Background Luteolin has been demonstrated to possess numerous biological effects. However, the effect of luteolin on LPS (Lipopolysaccharides) stimulation in CPEK cells has not been investigated. Hypothesis/Objectives An in vitro model of atopic canine dermatitis was used to identify the antioxidant effect of luteolin as a new treatment that is capable of improving the conditions of veterinary patients. Methods CPEK cells were treated with or without luteolin in the presence or absence of LPS. A cell viability assay was performed to test luteolin toxicity and the protective effect of luteolin after LPS stimulation. Additionally, enzyme‐linked immunosorbent assay (ELISA) kits were used to detect the levels of IL‐33, IL‐1β, IL‐6, and IL‐8. Results Luteolin was capable to significantly decrease levels expression of IL‐33, IL 1β, IL‐6, and IL‐8. Conclusions and clinical importance Luteolin could be a new pharmacological treatment for canine atopic dermatitis.